




RealRate

PHARMACEUTICAL 2026

Biofrontera Inc
Rank 109 of 178

us.com the alternative.com
PERFECT FOR AMERICAN COMPANIES AND WEBSITES TARGETING THE AMERICAN MARKET



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biofrontera Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biofrontera Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Biofrontera Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 129% points.

The company's Economic Capital Ratio, given in the ranking table, is 191%, being 39% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	18,083
Cost of Goods Sold	0
Intangible Assets	2,650
Liabilities, Current	11,895
Liabilities, Non-Current	1,249
Other Assets	5,673
Other Compr. Net Income	0
Other Expenses	11,608
Other Liabilities	4,940
Other Net Income	837
Other Revenues	41,705
Property and Equipment	2,158
Research and Development	3,719
Selling, General and Administrative Expense	37,751

Output Variable	Value in 1000 USD
Assets	28,564
Liabilities	18,084
Expenses	53,078
Revenues	41,705
Stockholders Equity	10,480
Net Income	-10,536
Comprehensive Net Income	-10,536
BaseVar	71,134
ECR before LimitedLiability	53%
Economic Capital Ratio	191%